Business
VIMAB: Revenue fell 17.5% in Q2, but major post-period deals are set to boost H2 results
VIMAB: Revenue fell 17.5% in Q2, but major post-period deals are set to boost H2 results
About this update from Vimab Group Ab
Q2 2025 saw a 17.5% revenue decline and negative net results, but operating losses narrowed. Post-period, a major subsidiary was sold and a large battery storage contract was secured, expected to significantly improve H2 results.Original document: This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.